Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

BACKGROUND: Currently, two pediatric pneumococcal conjugate vaccines are available in the private market of Malaysia—13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). This study aimed to eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiao Jun, Saha, Ashwini, Zhang, Xu-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568314/
https://www.ncbi.nlm.nih.gov/pubmed/28852326
http://dx.doi.org/10.1186/s12962-017-0079-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568314/
https://www.ncbi.nlm.nih.gov/pubmed/28852326
http://dx.doi.org/10.1186/s12962-017-0079-2

Ejemplares similares